Ivermectin fails to lower incidence of hospitalization in large COVID-19 study

Ivermectin did not lower the incidence of hospitalization among high-risk adults with COVID-19 enrolled in a large double-blind, randomized, placebo-controlled trial in Brazil, researchers reported in The New England Journal of Medicine.
The researchers said the trial of more than 3,500 patients will have a significant impact on the body of evidence for ivermectin as a potential therapy for COVID-19, which has generated a lot of controversy.
WHO, the FDA and the Infectious Diseases Society of America all recommend against its use.
“The evidence supporting the role of ivermectin in the

Ivermectin did not lower the incidence of hospitalization among high-risk adults with COVID-19 enrolled in a large double-blind, randomized, placebo-controlled trial in Brazil, researchers reported in The New England Journal of Medicine.
The researchers said the trial of more than 3,500 patients will have a significant impact on the body of evidence for ivermectin as a potential therapy for COVID-19, which has generated a lot of controversy.
WHO, the FDA and the Infectious Diseases Society of America all recommend against its use.
“The evidence supporting the role of ivermectin in the